Business Context and Reporting Period
This Form 8-K Current Report was filed by Madrigal Pharmaceuticals, Inc. on April 16, 2025. The report details a change in the role and compensatory arrangements of Dr. Rebecca Taub, the Company's Chief Medical Officer and President of Research and Development.
Key Financial Metrics
The filing does not provide general financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to executive compensation:
- Base Salary: $621,000 for the 2025 fiscal year.
- Target Bonus: 50% of the annual base salary (approximately $310,500), contingent on continued employment through the end of 2025.
Material Changes
Effective April 21, 2025, Dr. Taub is transitioning from her executive roles to a Senior Scientific and Medical Advisor position through December 31, 2025. She will continue to serve on the Board of Directors. This transition is accompanied by a new Severance and Change of Control Agreement.
Outlook, Risks, and Unusual Items
Compensatory Arrangements: Under the new agreement, if Dr. Taub experiences a "Qualifying Separation" (termination without cause or resignation for good reason), she is entitled to:
- Continuation of base salary for 12 months.
- A separation bonus equal to the target annual bonus, paid in 12 monthly installments.
- Full acceleration of vesting for all outstanding equity awards.
- Continuation of health benefits for 12 months.
If a Qualifying Separation occurs within one year of a "change of control," these benefits are payable in a lump sum. These benefits also apply if her employment is not extended beyond the End Date (December 31, 2025).
Investor Verification Checklist
- Verify the exact effective date of the role transition (April 21, 2025) and the end date of the advisory role (December 31, 2025).
- Confirm the total potential cash compensation exposure ($621,000 base + up to $310,500 bonus) for the remainder of 2025.
- Review the definitions of "cause" and "good reason" in the Severance and Change of Control Agreement to understand the triggers for the 12-month severance package.
- Assess the impact of the full acceleration of equity awards on the company's dilution and expense recognition if a qualifying separation occurs.